TITAN PHARMACEUTICALS INC Logo

TITAN PHARMACEUTICALS INC

Develops a long-term drug delivery implant for treating chronic central nervous system disorders.

TTNP | US

Overview

Corporate Details

ISIN(s):
US8883146065
LEI:
Country:
United States of America
Address:
400 OYSTER POINT BLVD, 94080 SAN FRANCISCO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Titan Pharmaceuticals, Inc. is a development-stage biopharmaceutical company that develops proprietary therapeutics for the treatment of select chronic diseases. The company's core technology is its clinically proven ProNeura® platform, a long-term, continuous drug delivery system. This platform is designed to deliver stable, non-fluctuating levels of medication for periods of up to one year from a single subcutaneous implant. Titan's research and development activities are focused on exploring new therapeutic applications for the ProNeura platform, with a primary emphasis on treating central nervous system disorders. In late 2023, the company announced a merger with Black Titan Corporation.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all TITAN PHARMACEUTICALS INC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for TITAN PHARMACEUTICALS INC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for TITAN PHARMACEUTICALS INC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Mochida Pharmaceutical Co.,Ltd. Logo
An R&D-driven company making drugs, skincare, and medical equipment for specialized fields.
Japan
4534
Modalis Therapeutics Corporation Logo
Develops epigenome editing therapies for genetic muscular, heart, and CNS disorders.
Japan
4883
Moderna, Inc. Logo
Pioneering mRNA science to create transformative medicines and vaccines for diverse diseases.
United States of America
MRNA
Molecular Partners AG Logo
Pioneering DARPin protein drugs for complex diseases in oncology and virology.
Switzerland
MOLN
Moleculin Biotech, Inc. Logo
Developing therapies for hard-to-treat tumors (like AML) and viruses.
United States of America
MBRX
Monte Rosa Therapeutics, Inc. Logo
Develops molecular glue degraders to target undruggable proteins in cancer and immune diseases.
United States of America
GLUE
Develops LNP drug delivery systems for severe diseases, offering R&D to GMP manufacturing support.
South Korea
322970
MoonLake Immunotherapeutics Logo
Developing Nanobody therapies for inflammatory and immunologic diseases like psoriatic arthritis.
United States of America
MLTX
MORISHITA JINTAN CO.,LTD. Logo
Manufactures health products and provides OEM/ODM services using advanced encapsulation technology.
Japan
4524
MorphoSys AG Logo
Biopharma company creating antibody therapies for oncology, with a focus on blood cancers.
Germany
MOR

Talk to a Data Expert

Have a question? We'll get back to you promptly.